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Immunization of mice with low doses of sheep red blood cells (SRBC) which are
suboptimal for antibody responses, leads to sensitization for delayed foot pad
reactions within 4 days (1-3) . These delayed-type hypersensitivity (DTH)
reactions cannot be elicited in mice which have been immunized with larger
doses of SRBC that are more optimal for antibody responses (3, 4). It has been
suggested that B-cell responses to high dose immunization cause suppression of
T-cell-mediated delayed foot pad reactions (3). In supportofthis notion, animals
pretreated with B-cell depleting doses of cyclophosphamide (2-300 mg/kg) have
markedly suppressed antibody responses and augmenteddelayed reactions (4-7).
We have studied delayed foot pad reactions of mice immunized with SRBC and
found that by lowering the dose ofcyclophosphamide pretreatment to 20 mg/kg,
delayed-type hypersensitivity can be augmented without affecting antibody
responses. Thus antibody is not the sole regulatory factor in mice immunized
with high doses of SRBC.
Groups of five to six male mice (5 wk old) were obtained from Jackson Laboratories (Bar Harbor,
Maine), andwere immunized intravenously with 0.2 ml of different concentrations ofwashed SRBC 1
wk after arrival. Cyclophosphamide (Cytoxan, Mead Johnson & Co., Evansville, Ind.) was dissolved
in sterile saline immediately before use andinjected by the intraperitoneal route as asingle dose of 20
mg/kg 1 day before immunization, or 200 mg/kg 2 days before immunization .
4 days after immunization, one foot pad per mousewas measured for thickness with a micrometer
(Brown & Sharps Mfg. Co., No. Kingston, R.I.) and was then tested by injection of 0.03 ml of 20%
SRBC in sterile saline. Theoriginal foot padthickness wascompared to subsequent measurements to
compute the percent increase in thickness. Animals were re-tested in the contralateral foot pad 10
days after immunization. Blood samples were obtained by capillary tube puncture of the retro-orbital
plexus 5 and 10 days after initial immunization. The resulting serum from individual mice was
twofold diluted in 0.025-ml volumes in microtray wells for measurement of hemagglutinating
antibody (HA) titers. Student's t test was used to compute statistical significance (P < 0.05) of HA
titers and DTH.
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Results
The data (Table I) show that in BDP mice a low dose of immunizing antigen
(0 .01% SRBC : about 2 x 105 erythrocytes), produced a much greater DTH
response than did a larger dose (1% SRBC) which was more optimal for antibody
production . (These delayed foot pad reactions achieved with low dose SRBC
immunization were maximal in these mice at 48 h, were specific for SRBC
compared to equivalent testing with horse, goose, or human erythrocytes ; were
unaccompanied by significant 4-h reactions; and could be transferred to
nonimmune mice with spleen cells and not sera [data not presented].) Cyclo-
phosphamide pretreatment in low doses (20 mg/kg) had little effect on delayed
foot pad reactions and hemagglutinating antibody production in the mice
immunized intravenously with 0.01% SRBC. On the other hand, this cyclophos-
phamide pretreatment administered to mice primed with 100-fold higher doses of
SRBC, markedly augmented the small DTH reactions, while vigorous IgG
antibody responses were unaffected or slightly increased. Other strains of mice
varied in the optimal SRBC dosage forDTH, and the onset and duration of these
reactions; but the ability of low dose cyclophosphamide to augment DTH
without affecting antibody responses was found in 10 other strains of mice (AKR,
DBA/2, B6AF,, AKD2F,, C57BL/6, BDF,, A, BALB-B, C3H/NB, and NZB) . The
BDP mice shown in TableI were selected from various strains enumerated above
as they best illustrated the general phenomenon .
TABLE I
Augmentation of Delayed-Type Hypersensitivity in Mice, by Doses of Cyclophosphamide
Which Do Not Affect Antibody Responses
Responses after foot pad testing at 4 days
* P << 0.0005 compared to equivalently immunized controls that were not pretreated with cyclophosphamide.
Table II shows the results of an experiment in which the immunizing dose of
SRBC and pretreatment dose of cyclophosphamide were varied in BDF, mice
and foot pad testing performed on day 4 and on day 10. As with BDP mice,
immunization with 0.01% SRBC led to optimal DTH reactions and negligible
4-day antibody responses. Immunization with supraoptimal SRBC doses (1% and
100%) led to suppressed DTH reactions, which were augmented by low dose
cyclophosphamide pretreatment without affecting the large antibody responses.
When mice immunized with the higher of these doses of SRBC were pretreated
with higher doses of cyclophosphamide (200 mg/kg), the antibody responses were
abolished but no further augmentation of DTH occured. Thus, the augmentation
of delayed hypersensitivity by cyclophosphamide pretreatment was largely
independent of its effect on antibody responses. Furthermore, mice immunized
Immunizing dose of
SRBC (0.2 ml)
Cyclophosphamide
pretreatment 48-h thickness
(%change 1 SE)
24-h HA
Plain
titer log,
+ 2 ME
0.01% 0 43 1 3 1 1 0.4 1 1 0
0.01% 20 mg/kg 43 1 6 1.3 1 0.5 1 1 0
1 .0% 0 15 1 1 5 .3 :±:0.5 4.5 1 1.2
1.0% 20 mg/kg 50 1 2* 6.3 1 0.5 6.3 1 0.5ASKENASE ET AL .
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TABLE 11
The Effect of Cyclophosphamide Pretreatment on Delayed Hypersensitivity and Antibody
Responses in BDF, Mice 4 and 10 Days after Intravenous Immunization with Various
Doses of SRBC
* Percent increase in footpad thickness at 24 h t SE.
$P < 0.005 compared to equivalently immunized controls that were not pretreated with cyclophosphamide.
with lower than optimal doses of SRBC (0.001 %), produced no detectable
antibody response at 4 days and also had augmented DTH responses when
pretreated with 20 mg/kg cyclophosphamide. Thus, DTH responses which were
suppressed by either high zone or low zone immunization with SRBC, could be
augmented by cyclophosphamide without affecting antibody responses.
On day 10, DTH reactions were still present in mice immunized with low doses
of SRBC but were decidedly less than reactions elicited at 4 days, and were
accompanied by appreciable antibody titers. Augmented DTH reactions were
now found principally in mice treated with the higher doses of cyclophosphamide
and antigen, and were associated with greatly depressed mean antibody titers.
Thus, at day 10 in contrast to day 4, augmented DTH by cyclophosphamide
correlated with depressed antibody responses. However, examination of the
individual mice which had augmented DTH reactions on day 10 showed that
augmentation was as great in those nine mice with antibody (36 ~L 3% DTH; HA
titer 4 ~E 0.4) as it was in the 12 mice with absent antibody responses (39 t 4%
DTH) . Thus, even the augmented DTH produced by greater suppressive doses of
cyclophosphamide was not correlated with the degree of suppression of the
antibody response .
Discussion
We have shown in a variety of mouse strains that pretreatment with a very small
dose of cyclophosphamide can augment the delayed reactions elicited by sheep
cell injection in the foot pads of mice immunizedwith greater than optimal doses
of antigen. These small doses of cyclophosphamide have no detectable suppres-
sive effect on the production of hemagglutinating antibodies at the time of
Immunizing dose
of SRBC
Cyclophosphamide
pretreatment At 4
DTH*
Responses after
days
HA titer
foot Pad testing
At 10
DTH*
days
HAtiter
% log, % log,
0.001% 0 14t 2 0 13 t4 6.8 0.3
0.001% 20 mg/kg 41 t 7$ 0 23 f 5 7.3 f 0.3
0.01% 0 60 1 7 0 32 1 3 7.8 1 02
0.01% 20 mg/kg 54 t 4 0.8 28 t 2 8.5 t 0.2
1.0% 0 -2t 3 6.51 0.2 111 3 7 .61 0.2
1.0% 20 mg/kg 14 f 5$ 6.5 f 0.2 10+ 3 7.5 t 0.3
1.0% 200 mg/kg 13 f 2$ 0 46 f 5$ 2.4 t 0.7$
100% 0 4f 3 6.21 0.5 5f 1 8.31 0.2
100% 20 mg/kg 10 1 3 5.2 1 0.3 5 1 1 8 1 0
100% 200 mg/kg 15 t 2$ 0.7 34 = 2$ 0$700
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testing for delayed sensitivity . If cyclophosphamide augments the DTH response
by removing a suppressor influence, it would appear that antibody is not the sole
suppressor of these reactions. Other workers have shown that higher doses of
cyclophosphamide also potentiate delayed reactions and concomitantly depress
antibody responses: Our work suggests that the association of these two effects of
cyclophosphamide are not necessarily causatively related. In fact, in several
instances delayed foot pad reactions and antibody responses were both aug-
mented by cyclophosphamide pretreatment . In addition, mice immunized with
suboptimal doses of SRBC produced no detectable antibody at 4 days and also
had DTH that was augmented by cyclophosphamide. It is intriguing to speculate
that this low zone suppression of DTH, which was uncovered by cyclophospha-
mide pretreatment, is related to low zone tolerance for antibody production.
A number of manipulations produce reciprocal effects on antibody formation
and delayed hypersensitivity . In particular, acetoacetylation or periodination of
flagellin or SRBC (8, 9), hapten conjugation of proteins (10) and glutaraldehyde
pretreatment (11), or macrophage preincubation of SRBC (12) augments delayed
reactions and suppresses antibody responses. These modifications of antigen may
mimic the effects produced by decreasing antigen doses as employed in this
study. Mice immunized with 100% SRBC were particularly intriguing; pretreat-
ment of these mice with 200 mg/kg of cyclophosphamide, similar to antigen
modification, led to complete antibody tolerance (the mice made no antibody at
day 10 after priming on day 0 and challenge on day 4) although good DTH
responses could be elicited.
It is now quite well established that T cells can have both augmentative and
suppressive effects on other T cells as well as on B cells, (reviewed in 13). Such T
cells can be thought of as regulators of the immune response. It is possible that
antigen dose and/or other molecular factors may induce regulatory T cells to
produce one type of immunity and concomitantly suppress another. Doses of
antigen which are optimal for antibody production by B cells may induce regula-
tory T cells to suppress delayed hypersensitivity responses independently of the
ensuing antibody response . Thus, the frequently noted reciprocal relationship
between antibody formation and delayed hypersensitivity maybe, at least in part,
regulated by T cells directly, without indirect participation of feedback signals
from target cells (i .e . antibody).
B-cell products may play an additional role in suppression of delayed
hypersensitivity since it is well known that antibody can be immunosuppressive.
B-cell products could act directly to suppress delayed hypersensitivity or could
act to signal regulatory T cells to exert suppressor effects; as has been recently
reported (14,15) .
Although initial reports indicated that cyclophosphamide selectively depleted
nonthymus-dependent areas of lymphoid tissues, depressed antibody responses,
and was not toxic for T cells, more recent information suggests that subpopula-
tions of T cells are rapidly dividing (16) and thus probably sensitive to cyclophos-
phamide (17).
Although low dose cyclophosphamide pretreatment failed to produce reduc-
tions in hemagglutinating antibody titers, subpopulations of B cells producing
antibodies of specialized classes or other B-cells products, could have been af-ASKENASE ET AL.
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fected. One must keep open the possibility that small quantities or local produc-
tion of some B-cell products may be particularly specialized to act as regulatory
molecules. Further studies are required to rule out this possibility. However, it is
quite clear from the results we have presented that gross changes in the delayed
hypersensitivity response can be produced by cyclophosphamide pretreatment
without the production of concomitant gross alterations in the antibody re-
sponse.
The authors gratefully acknowledge the technical assistance of Ellen Searle and David Tauben, and
are also indebted to Dr. Charles Metzler .
Receiued for publication 7 October 1974.
Summary
Mice immunized with more SRBC than are required to produce optimal
delayed-type hypersensitivity reactions, developed good antibody responses and
poor delayed foot pad reactions. Cyclophosphamide treatment in low doses (20
mg/kg) before immunization, augmented the delayed-type hypersensitivity
without affecting antibody responses. Cyclophosphamide did not augment
delayed responses to optimal doses of SRBC (0.01%), but did augment the
delayed hypersensitivity response ofmice immunized with a suboptimal antigen
dose (0.001%); which produced no detectable antibody response with or without
cyclophosphamide pretreatment. These results suggest that antibody feedback is
not the sole regulator of delayed reactions; the possibility that suppressor T cells
may also be involved is discussed.
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